Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence

Bayer’s experimental stroke treatment, asundexian, delivered strong results in the Phase III OCEANIC-STROKE trial, prompting renewed optimism for the pharmaceutical giant. Analysts, including Goldman Sachs’ James Quigley, described the data as “transformational,” projecting that the drug could generate as much as €3 billion in annual sales once commercialized. Following the announcement, Bayer’s shares surged nearly 9% in early European trading, reflecting investor confidence in the company’s expanding cardiovascular pipeline.

Asundexian met all primary trial endpoints, significantly reducing the risk of recurrent strokes without increasing the likelihood of major bleeding compared to placebo. More than 12,300 patients participated in the randomized, double-blind study, all having previously suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Importantly, both the investigational drug and placebo groups received standard antiplatelet therapy, underscoring the drug’s potential to complement current stroke-prevention treatments.

Quigley noted that removing the risk adjustment tied to asundexian from his valuation model increased his discounted cash flow estimate for Bayer by roughly 13%. He added that this successful readout is the first of two near-term catalysts expected to help close the gap between Bayer’s current stock price and what he views as the true value of its business units. The next potential boost could come from an upcoming recommendation by the U.S. solicitor general related to the company’s ongoing glyphosate litigation.

The results of the OCEANIC-STROKE trial address a major global health burden. Each year, around 12 million people worldwide suffer a stroke, with up to 30% experiencing a recurrent event. One in five survivors faces another stroke within five years, and recurrent ischemic strokes often lead to more severe disability and higher mortality. According to principal investigator Mike Sharma of McMaster University, the high risk of recurrence highlights the urgent need for safer and more effective prevention strategies.

Asundexian functions by selectively inhibiting Factor XIa, a protein involved in blood clot growth. Because this protein plays only a minor role in normal clotting that stops bleeding, researchers believe the drug can reduce stroke-causing clots without significantly elevating bleeding risk. This marks the first time a Factor XIa inhibitor has successfully completed a Phase III study.

The FDA has already granted asundexian Fast Track Designation, though it is not yet approved in any country.